MDMA After the Rejection: What the 2024 FDA Decision Actually Means

“The FDA rejected the first psychedelic NDA in August 2024. The reasons were methodological, not efficacy-based. Whether this is regulatory caution or regulatory failure is the most important contested question in the field.”

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee voted 10-1 that the evidence did not support approval of MDMA-assisted therapy for PTSD. In August 2024, the FDA issued a Complete Response Letter declining to approve the sponsor's MDMA application, the first formal application to approve a psychedelic-assisted therapy.

The data: the Phase 3 trials (MAPP1 and MAPP2) enrolled 263 participants with severe PTSD. In MAPP1, 67% of the MDMA group no longer met PTSD diagnostic criteria at follow-up, compared to 32% of placebo. In MAPP2, 71% versus 48%. The treatment differences were statistically significant. The effect sizes were large by psychiatric standards.

The FDA's concerns were not about whether MDMA helped participants. They were about whether the trials demonstrated that MDMA specifically, independent of the intensive psychotherapy surrounding it, was responsible for the benefit, and whether the safety characterization was adequate.

The unblinding problem: participants who receive active MDMA know they've received it, the phenomenological effects are unmistakable. This breaks the double-blind standard that FDA drug approvals depend on. If participants know they've received the active drug, therapist and patient expectancy effects cannot be controlled. The measured treatment difference might be partly or largely attributable to expectancy rather than pharmacology.

The committee was also concerned about therapist boundary violations: reports of therapists engaging in inappropriate conduct with MDMA-treated patients during sessions, including the high-profile accusations against therapists at several trial sites. The FDA found that the safety monitoring for therapist behavior was inadequate.

The FDA's position, as expressed in the Complete Response Letter, was not that MDMA doesn't help people with PTSD. It was that the current trial design cannot demonstrate what specifically causes the benefit in a way that meets FDA standards for drug approval.

David Yaden and colleagues at Johns Hopkins are cited as publishing a 2024 perspective in Nature Mental Health (Source not found; under review) arguing that the FDA's methodological standards were appropriate and that the field needed to develop better trial designs, including active placebos that mimic some phenomenological features of MDMA without the therapeutic effects, and more careful separation of drug and psychotherapy components.

MAPS and others have argued the opposite: that the FDA's standards are impossible to meet for a drug whose mechanism of action involves the subjective experience itself, and that the unblinding problem is a feature of the treatment rather than a methodological flaw to be designed around.

Jay Stevens wrote in Storming Heaven about a research program ended not by scientific failure but by political conditions. The MDMA situation is structurally different: the political conditions in 2024 are more favorable to psychedelic therapy than they were in 1968. The challenge is methodological, not political. But the result, a promising clinical program unable to achieve approval despite positive efficacy data, has structural similarities.

As of mid-2026, the sponsor is working on the design of an additional Phase 3 trial that addresses the FDA's methodological concerns. Whether an adequate design is possible, and whether the company can fund it, are open questions. MDMA remains Schedule I in the US while Australia has approved it for clinical use. The gap between the evidence and the approval will persist until the methodological problem is solved or the approval standard is revised.

Sources

• FDA advisory committee briefing documents, MDMA-assisted therapy application (June 2024)
• Mithoefer et al., Lancet Psychiatry (2018)
• Mitchell et al., Nature Medicine (2021)
• Yaden et al., Nature Mental Health (2024) [Source not found; under review]